HMG (Human Menopausal Gonadotropin)
Human Menopausal Gonadotropin (HMG) is a medication containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH), typically extracted from the urine of postmenopausal women. It is widely used in reproductive medicine to stimulate ovulation in women and spermatogenesis in men, often as part of assisted reproductive technologies (ART) or hypogonadism treatments.
01Dosing reference
02Mechanism of action
FSH and LH receptor activation
HMG binds to FSH receptors on Sertoli cells (in men) or granulosa cells (in women) and LH receptors on Leydig cells (in men) or theca cells (in women).
Gonadal stimulation
In men, it stimulates testosterone production and sperm maturation. In women, it promotes ovarian follicle development and maturation.
Fertility restoration
By providing exogenous gonadotropins, HMG can bypass hypothalamic-pituitary dysfunction to restore fertility and sex hormone production.
03Human evidence
HMG effectively stimulates spermatogenesis in men with hypogonadotropic hypogonadism.
Clinical trials show that when combined with hCG, HMG can induce sperm production and restore fertility in men with pituitary or hypothalamic dysfunction.
HMG is highly effective for controlled ovarian hyperstimulation in women undergoing IVF.
Extensive clinical use and trials demonstrate its efficacy in producing multiple mature follicles for egg retrieval, though it carries a risk of ovarian hyperstimulation syndrome (OHSS).
04Preclinical evidence
HMG administration in animal models of hypogonadism restores testicular volume and spermatogenesis.
Rodent studies evaluating the synergistic effects of FSH and LH on testicular function.
HMG promotes follicular growth and steroidogenesis in isolated animal ovaries.
In vitro and in vivo animal models used to study the direct effects of gonadotropins on ovarian tissue.
05What is known vs. unknown
- Contains a 1:1 ratio of FSH and LH activity.
- Extracted and purified from the urine of postmenopausal women.
- Used in combination with hCG to treat male infertility caused by hypogonadotropic hypogonadism.
- A cornerstone medication in assisted reproductive technologies (ART) like IVF for women.
- The optimal dosing protocols for male infertility can vary significantly and may require months of treatment before spermatogenesis is achieved.
- Carries a risk of ovarian hyperstimulation syndrome (OHSS) in women, requiring careful monitoring.
- Sourcing from human urine raises theoretical concerns about batch consistency and rare impurities, though modern purification is highly advanced.
06Safety & regulatory context
07Compared with hCG (Human Chorionic Gonadotropin)
08Glossary
09Knowledge check
10Sources
More in Hormonal Health
Kisspeptin-10
Kisspeptin-10 is a potent neuropeptide that acts as an upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Research shows it stimulates the release of gonadotropin-releasing hormone (GnRH), subsequently increasing luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels. It is heavily studied for its potential in treating infertility, hypogonadism, and reproductive disorders.
Gonadorelin
Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH). It stimulates the anterior pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the gonads to produce testosterone and sperm in males, and estrogen and eggs in females.
hCG (Human Chorionic Gonadotropin)
hCG is a hormone naturally produced during pregnancy that mimics luteinizing hormone (LH) in the body. In research and clinical settings, it is widely used to stimulate testosterone production, preserve fertility, and treat hypogonadism in men, as well as to induce ovulation in women.